Rebekah Sayers

Exploring the power of ZT Scan DIA

Feb 7, 2025 | Blogs, Life Science Research, Proteomics, ZenoTOF 7600+ system | 0 comments

Read time: 2 minutes

In a recent presentation, Tim Heymann from Mann Lab at the Max Planck Institute of Biochemistry shared his first impressions of ZT Scan DIA, the novel data-independent acquisition strategy from SCIEX, highlighting its innovative approach and significant benefits for proteomics research. Let’s dive into the key points from his insightful talk.

Understanding ZT Scan DIA

ZT Scan DIA offers a more efficient scan mode than regular SWATH DIA. The major difference lies in the continuous scan with overlapping windows, which eliminates overhead time and provides an additional Q1 scanning dimension. This results in a more efficient and detailed analysis, allowing researchers to distinguish between different precursors even if they appear to coelute.

Benchmarking ZT Scan DIA

Tim’s initial benchmarks focused on three performance assessments with a K562 digest: bulk-level analysis, lower sample inputs and short gradients. Using the Evosep One system coupled to the ZenoTOF 7600+ system, he tested various setups for higher coverage and throughput. The results were promising, showing a noticeable increase in identifications (IDs) at both the precursor and protein group levels.

Performance at different loads and gradients

ZT Scan DIA significantly boosted performance, especially at lower sample loads and shorter LC gradients. For instance, at 50 nanograms, there was a 50% gain in protein IDs, and at 500 SPD, the increase in quantifiable precursors was almost 100%. This robust performance across different settings highlights the versatility and efficiency of ZT Scan DIA.

Insights into phosphoproteomics

When analyzing phosphopeptides, ZT Scan DIA showed more than 10% gains in phosphosite detections, particularly in the lower abundant range. Although the overlap with Zeno SWATH DIA was lower, this was expected due to the enrichment process in phosphoproteomics. The enhanced selectivity of ZT Scan DIA provides more confidence in identifying phosphosites.

Leveraging AlphaDIA and Transfer Learning for data processing

Tim also discussed using AlphaDIA and Transfer Learning to maximize data analysis. By adapting models to different patterns and setups, AlphaDIA can significantly improve identification rates. Although current limitations prevent full access to the Q1 scanning dimension, ongoing developments promise even better performance in the future.

Conclusion

Overall, ZT Scan DIA represents a substantial advancement in proteomics research. It offers a performance boost that becomes more pronounced at lower loads and faster gradients. With its innovative approach and robust results, ZT Scan DIA is poised to impact the field significantly.

Watch Tim’s presentation here

Why SCIEX partners with experts around the world

Innovation in mass spectrometry does not happen in isolation. Some of the most impactful scientific advances emerge from highly specialized research communities – proteomics experts developing new peptide identification workflows, metabolomics researchers curating spectral databases, toxicologists building compound libraries, and biopharma scientists creating novel characterization methods.

Managing ADC characterization: The challenge of turning complexity into confidence

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

3 reasons ZT Scan DIA is changing the game in metabolomics

For years, metabolomics researchers have faced a frustrating reality: modern high-resolution mass spectrometers can detect tens of thousands of molecular features, yet only a fraction can be confidently identified. The challenge is no longer finding molecules. It is generating the high-quality MS/MS data needed to confidently assign structures and extract meaningful biological insights.

Posted by

Rebekah Sayers

I developed a foundational understanding of biochemistry during my undergraduate studies before gaining a masters in molecular and cellular biophysics, and finally obtaining my Ph.D conducting in-depth proteomics research in peanut allergy. I started at SCIEX in the applications support team, later being promoted to the application lead for life science research in EMEAI. I am currently leading global strategic marketing efforts, contributing to the advancement of small molecule OMICS. This role is pivotal in bridging the gap between scientific innovation and market demand, ensuring that products and workflows not only meet the needs of the market but also stand out in a competitive landscape.

0 Comments